A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- 1 May 2008
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 109 (2), 182-186
- https://doi.org/10.1016/j.ygyno.2008.01.009
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancerGynecologic Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitorBritish Journal of Cancer, 2006
- Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patientsBMC Cancer, 2006
- Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cellsCancer Letters, 2006
- The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinProceedings of the National Academy of Sciences, 2002
- Histone Deacetylase Inhibitors Promote Apoptosis and Differential Cell Cycle Arrest in Anaplastic Thyroid Cancer CellsThyroid®, 2001
- Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of CancersBlood Cells, Molecules, and Diseases, 2001
- Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II TrialGynecologic Oncology, 1998
- Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology GroupGynecologic Oncology, 1998